Sustained-Release Corticosteroid Options
Joint Authors
Cabrera, Mariana
Yeh, Steven
Albini, Thomas
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-07-22
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Sustained-release corticosteroid treatment has shown to be a promising strategy for macular edema due to retinovascular disease (i.e., diabetes and retinal vein occlusion) and for the treatment of noninfectious posterior uveitis.
Clinicians now have the option of three sustained-release corticosteroid implants: Ozurdex (Allergan Inc., Irvine, CA) which releases dexamethasone and two devices that release fluocinolone acetonide, Retisert (Bausch & Lomb, Rochester, NY), and Iluvien (Alimera Science, Alpharetta, GA).
Each has different physical characteristics and duration effect and has been approved for different indications.
Herein we provide a summary of the current clinical knowledge regarding these implants.
American Psychological Association (APA)
Cabrera, Mariana& Yeh, Steven& Albini, Thomas. 2014. Sustained-Release Corticosteroid Options. Journal of Ophthalmology،Vol. 2014, no. 2014, pp.1-5.
https://search.emarefa.net/detail/BIM-1042416
Modern Language Association (MLA)
Cabrera, Mariana…[et al.]. Sustained-Release Corticosteroid Options. Journal of Ophthalmology No. 2014 (2014), pp.1-5.
https://search.emarefa.net/detail/BIM-1042416
American Medical Association (AMA)
Cabrera, Mariana& Yeh, Steven& Albini, Thomas. Sustained-Release Corticosteroid Options. Journal of Ophthalmology. 2014. Vol. 2014, no. 2014, pp.1-5.
https://search.emarefa.net/detail/BIM-1042416
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1042416
